Atlas Trials

Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

Clinical trial NCT06563778 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06563778
Sponsor
Chinese PLA General Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Start date
2024-09-01
Primary completion
2026-09-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.